Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice.
Level 5 - mechanism / opinion, no new human data
Narrative review and clinical practice guidance without original empirical data or systematic search methodology.
What was done
This paper reviewed guidelines and clinical evidence regarding high-sensitivity C-reactive protein (hsCRP) measurement, focusing on Centers for Disease Control and American Heart Association recommendations for global cardiovascular risk prediction, clinical cutoff interpretation, and therapeutic interventions.
What was found
The review reports established hsCRP stratification thresholds: <1 mg/L for lower risk, 1 to 3 mg/L for moderate risk, and >3 mg/L for higher cardiovascular risk across all Framingham Risk Score tiers and metabolic syndrome categories. Interventions noted to lower hsCRP include diet, exercise, smoking cessation, statin therapy, and improved glycemic control. hsCRP is also identified as a prognostic marker in acute coronary syndromes, post-angioplasty, and long-term post-infarction care. No new numerical trial data or effect estimates were provided in the abstract.
Why it matters
It outlines practical guidance for incorporating inflammatory biomarker testing alongside cholesterol profiles into clinical cardiovascular risk assessment.
Limits
The abstract describes a narrative review and expert clinical overview rather than a primary study or systematic review. No original patient data, sample sizes, confidence intervals, or search criteria are reported.
Cited by
- supports A high-sensitivity C-reactive protein (hs-CRP) level above 1 to 2 mg/L indicates a chronic inflammatory condition.